Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 177

1.

A possible link between polyunsaturated fatty acids and uremic toxins from the gut microbiota in hemodialysis patients: A hypothesis.

Kemp JA, Esgalhado M, Macedo RA, Regis B, Damasceno NRT, da Silva Torres EAF, Gonçalinho GHF, Borges NA, Nakao LS, Fouque D, Mafra D.

Hemodial Int. 2019 Apr;23(2):189-197. doi: 10.1111/hdi.12725. Epub 2019 Feb 19.

PMID:
30779317
2.

Could resistant starch supplementation improve inflammatory and oxidative stress biomarkers and uremic toxins levels in hemodialysis patients? A pilot randomized controlled trial.

Esgalhado M, Kemp JA, Azevedo R, Paiva BR, Stockler-Pinto MB, Dolenga CJ, Borges NA, Nakao LS, Mafra D.

Food Funct. 2018 Dec 13;9(12):6508-6516. doi: 10.1039/c8fo01876f.

PMID:
30468238
3.

Corrigendum to molecular genetics and emerging therapies for retinitis pigmentosa: Basic research and clinical perspective progress in retinal and eye research (2018) Vol 63,107-131.

Dias MF, Joo K, Kemp JA, Fialho SL, da Silva Cunha A Jr, Woo SJ, Kwon YJ.

Prog Retin Eye Res. 2018 Sep;66:220-221. doi: 10.1016/j.preteyeres.2018.08.001. Epub 2018 Aug 11. No abstract available.

PMID:
30104149
4.

Anti-Tau Monoclonal Antibodies Derived from Soluble and Filamentous Tau Show Diverse Functional Properties in vitro and in vivo.

Vandermeeren M, Borgers M, Van Kolen K, Theunis C, Vasconcelos B, Bottelbergs A, Wintmolders C, Daneels G, Willems R, Dockx K, Delbroek L, Marreiro A, Ver Donck L, Sousa C, Nanjunda R, Lacy E, Van De Casteele T, Van Dam D, De Deyn PP, Kemp JA, Malia TJ, Mercken MH.

J Alzheimers Dis. 2018;65(1):265-281. doi: 10.3233/JAD-180404.

PMID:
30040731
5.

Molecular genetics and emerging therapies for retinitis pigmentosa: Basic research and clinical perspectives.

Dias MF, Joo K, Kemp JA, Fialho SL, da Silva Cunha A Jr, Woo SJ, Kwon YJ.

Prog Retin Eye Res. 2018 Mar;63:107-131. doi: 10.1016/j.preteyeres.2017.10.004. Epub 2017 Oct 31. Review. Erratum in: Prog Retin Eye Res. 2018 Sep;66:220-221.

PMID:
29097191
6.

Emergence of early alterations in network oscillations and functional connectivity in a tau seeding mouse model of Alzheimer's disease pathology.

Ahnaou A, Moechars D, Raeymaekers L, Biermans R, Manyakov NV, Bottelbergs A, Wintmolders C, Van Kolen K, Van De Casteele T, Kemp JA, Drinkenburg WH.

Sci Rep. 2017 Oct 27;7(1):14189. doi: 10.1038/s41598-017-13839-6.

7.

Short-chain fatty acids: a link between prebiotics and microbiota in chronic kidney disease.

Esgalhado M, Kemp JA, Damasceno NR, Fouque D, Mafra D.

Future Microbiol. 2017 Nov;12:1413-1425. doi: 10.2217/fmb-2017-0059. Epub 2017 Oct 13. Review.

PMID:
29027814
8.

The physics of unwound and wound strings on the electric guitar applied to the pitch intervals produced by tremolo/vibrato arm systems.

Kemp JA.

PLoS One. 2017 Sep 21;12(9):e0184803. doi: 10.1371/journal.pone.0184803. eCollection 2017.

9.

Age-dependent concomitant changes in synaptic dysfunction and GABAergic pathway in the APP/PS1 mouse model.

Oyelami T, Bondt A, den Wyngaert IV, Hoorde KV, Hoskens L, Shaban H, Kemp JA, Drinkenburg WH.

Acta Neurobiol Exp (Wars). 2016;76(4):282-293.

10.

Translational neurophysiological markers for activity of the metabotropic glutamate receptor (mGluR2) modulator JNJ-40411813: Sleep EEG correlates in rodents and healthy men.

Ahnaou A, de Boer P, Lavreysen H, Huysmans H, Sinha V, Raeymaekers L, Van De Casteele T, Cid JM, Van Nueten L, Macdonald GJ, Kemp JA, Drinkenburg WH.

Neuropharmacology. 2016 Apr;103:290-305. doi: 10.1016/j.neuropharm.2015.11.031. Epub 2015 Dec 12.

PMID:
26686390
11.

"Combo" nanomedicine: Co-delivery of multi-modal therapeutics for efficient, targeted, and safe cancer therapy.

Kemp JA, Shim MS, Heo CY, Kwon YJ.

Adv Drug Deliv Rev. 2016 Mar 1;98:3-18. doi: 10.1016/j.addr.2015.10.019. Epub 2015 Nov 4. Review.

PMID:
26546465
12.

Intracerebral injection of preformed synthetic tau fibrils initiates widespread tauopathy and neuronal loss in the brains of tau transgenic mice.

Peeraer E, Bottelbergs A, Van Kolen K, Stancu IC, Vasconcelos B, Mahieu M, Duytschaever H, Ver Donck L, Torremans A, Sluydts E, Van Acker N, Kemp JA, Mercken M, Brunden KR, Trojanowski JQ, Dewachter I, Lee VM, Moechars D.

Neurobiol Dis. 2015 Jan;73:83-95. doi: 10.1016/j.nbd.2014.08.032. Epub 2014 Sep 16.

13.

Wave separation in the trumpet under playing conditions and comparison with time domain finite difference simulation.

Kemp JA, Bilbao S, McMaster J, Smith RA.

J Acoust Soc Am. 2013 Aug;134(2):1395-406. doi: 10.1121/1.4812254.

PMID:
23927135
14.

Time domain wave separation using multiple microphones.

Kemp JA, van Walstijn M, Campbell DM, Chick JP, Smith RA.

J Acoust Soc Am. 2010 Jul;128(1):195-205. doi: 10.1121/1.3392441.

PMID:
20649215
15.

Patient and hospital factors associated with use of sphincter-sparing surgery for rectal cancer.

Paquette IM, Kemp JA, Finlayson SR.

Dis Colon Rectum. 2010 Feb;53(2):115-20. doi: 10.1007/DCR.0b013e3181bc98a1.

PMID:
20087084
16.

Early-onset and robust amyloid pathology in a new homozygous mouse model of Alzheimer's disease.

Willuweit A, Velden J, Godemann R, Manook A, Jetzek F, Tintrup H, Kauselmann G, Zevnik B, Henriksen G, Drzezga A, Pohlner J, Schoor M, Kemp JA, von der Kammer H.

PLoS One. 2009 Nov 20;4(11):e7931. doi: 10.1371/journal.pone.0007931.

17.

Outcomes of laparoscopic and open colectomy: a national population-based comparison.

Kemp JA, Finlayson SR.

Surg Innov. 2008 Dec;15(4):277-83. doi: 10.1177/1553350608327171.

PMID:
19036732
18.

Nationwide trends in laparoscopic colectomy from 2000 to 2004.

Kemp JA, Finlayson SR.

Surg Endosc. 2008 May;22(5):1181-7. doi: 10.1007/s00464-007-9732-8. Epub 2008 Feb 1.

PMID:
18246394
19.

Trends in adoption of laparoscopic cholecystectomy in rural versus urban hospitals.

Kemp JA, Zuckerman RS, Finlayson SR.

J Am Coll Surg. 2008 Jan;206(1):28-32. Epub 2007 Sep 17.

PMID:
18155565
20.

Asymmetric synthesis and receptor pharmacology of the group II mGlu receptor ligand (1S,2R,3R,5R,6S)-2-amino-3-hydroxy-bicyclo[3.1.0]hexane-2,6-dicarboxylic acid-HYDIA.

Woltering TJ, Adam G, Huguenin P, Wichmann J, Kolczewski S, Gatti S, Bourson A, Kew JN, Richards G, Kemp JA, Mutel V, Knoflach F.

ChemMedChem. 2008 Feb;3(2):323-35.

PMID:
18058780
21.

Familial risk and colorectal cancer screening health beliefs and attitudes in an insured population.

Palmer RC, Emmons KM, Fletcher RH, Lobb R, Miroshnik I, Kemp JA, Bauer M.

Prev Med. 2007 Nov;45(5):336-41. Epub 2007 Jul 26.

PMID:
17804048
22.

Screening patients with a family history of colorectal cancer.

Fletcher RH, Lobb R, Bauer MR, Kemp JA, Palmer RC, Kleinman KP, Miroshnik I, Emmons KM.

J Gen Intern Med. 2007 Apr;22(4):508-13.

23.

Life expectancy benefits of gastric bypass surgery.

Pope GD, Finlayson SR, Kemp JA, Birkmeyer JD.

Surg Innov. 2006 Dec;13(4):265-73.

PMID:
17227925
24.

[The South African Dental Association and dentists in the field].

Kemp JA.

SADJ. 2001 Jan;56(1):10-1; author reply. Afrikaans. No abstract available.

PMID:
16894678
25.

Glutamate- and GABA-based CNS therapeutics.

Foster AC, Kemp JA.

Curr Opin Pharmacol. 2006 Feb;6(1):7-17. Epub 2005 Dec 22. Review.

PMID:
16377242
26.

Controlled trial of interventions to increase testing and treatment for Helicobacter pylori and reduce medication use in patients with chronic acid-related symptoms.

Majumdar SR, Ross-Degnan D, Farraye FA, Lee M, Kemp JA, Lecates RF, Henning JM, Tunis SR, Schrammel P, Soumerai SB.

Aliment Pharmacol Ther. 2005 Apr 15;21(8):1029-39.

27.

Evidence for improved performance in cognitive tasks following selective NR2B NMDA receptor antagonist pre-treatment in the rat.

Higgins GA, Ballard TM, Enderlin M, Haman M, Kemp JA.

Psychopharmacology (Berl). 2005 Apr;179(1):85-98. Epub 2005 Mar 10.

PMID:
15759152
28.

Ionotropic and metabotropic glutamate receptor structure and pharmacology.

Kew JN, Kemp JA.

Psychopharmacology (Berl). 2005 Apr;179(1):4-29. Epub 2005 Feb 25. Review. Erratum in: Psychopharmacology (Berl). 2005 Oct;182(2):320.

PMID:
15731895
29.

Human C-reactive protein increases cerebral infarct size after middle cerebral artery occlusion in adult rats.

Gill R, Kemp JA, Sabin C, Pepys MB.

J Cereb Blood Flow Metab. 2004 Nov;24(11):1214-8.

PMID:
15545914
30.

Pharmacological manipulation of mGlu2 receptors influences cognitive performance in the rodent.

Higgins GA, Ballard TM, Kew JN, Richards JG, Kemp JA, Adam G, Woltering T, Nakanishi S, Mutel V.

Neuropharmacology. 2004 Jun;46(7):907-17.

PMID:
15081787
31.

Antiparkinsonian activity of Ro 25-6981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson's disease.

Löschmann PA, De Groote C, Smith L, Wüllner U, Fischer G, Kemp JA, Jenner P, Klockgether T.

Exp Neurol. 2004 May;187(1):86-93.

PMID:
15081591
32.

Pharmacological and genetic evidence indicates that combined inhibition of NR2A and NR2B subunit containing NMDA receptors is required to disrupt prepulse inhibition.

Spooren W, Mombereau C, Maco M, Gill R, Kemp JA, Ozmen L, Nakanishi S, Higgins GA.

Psychopharmacology (Berl). 2004 Aug;175(1):99-105. Epub 2004 Feb 20.

PMID:
14985927
33.

Chronic acid-related disorders are common and underinvestigated.

Majumdar SR, Soumerai SB, Farraye FA, Lee M, Kemp JA, Henning JM, Schrammel P, LeCates RF, Ross-Degnan D.

Am J Gastroenterol. 2003 Nov;98(11):2409-14.

PMID:
14638341
34.

Identification of critical residues in the amino terminal domain of the human NR2B subunit involved in the RO 25-6981 binding pocket.

Malherbe P, Mutel V, Broger C, Perin-Dureau F, Kemp JA, Neyton J, Paoletti P, Kew JN.

J Pharmacol Exp Ther. 2003 Dec;307(3):897-905. Epub 2003 Oct 8.

PMID:
14534359
35.

PS2APP transgenic mice, coexpressing hPS2mut and hAPPswe, show age-related cognitive deficits associated with discrete brain amyloid deposition and inflammation.

Richards JG, Higgins GA, Ouagazzal AM, Ozmen L, Kew JN, Bohrmann B, Malherbe P, Brockhaus M, Loetscher H, Czech C, Huber G, Bluethmann H, Jacobsen H, Kemp JA.

J Neurosci. 2003 Oct 1;23(26):8989-9003.

36.

The voltage-dependent anion channel is the target for a new class of inhibitors of the mitochondrial permeability transition pore.

Cesura AM, Pinard E, Schubenel R, Goetschy V, Friedlein A, Langen H, Polcic P, Forte MA, Bernardi P, Kemp JA.

J Biol Chem. 2003 Dec 12;278(50):49812-8. Epub 2003 Sep 2.

37.
38.

Identification and characterization of a novel splice variant of the metabotropic glutamate receptor 5 gene in human hippocampus and cerebellum.

Malherbe P, Kew JN, Richards JG, Knoflach F, Kratzeisen C, Zenner MT, Faull RL, Kemp JA, Mutel V.

Brain Res Mol Brain Res. 2002 Dec 30;109(1-2):168-78.

PMID:
12531526
39.

NMDA receptor pathways as drug targets.

Kemp JA, McKernan RM.

Nat Neurosci. 2002 Nov;5 Suppl:1039-42. Review.

PMID:
12403981
40.
41.

Pharmacological characterization of Ro 63-1908 (1-[2-(4-hydroxy-phenoxy)-ethyl]-4-(4-methyl-benzyl)-piperidin-4-ol), a novel subtype-selective N-methyl-D-aspartate antagonist.

Gill R, Alanine A, Bourson A, Buttelmann B, Fischer G, Heitz MP, Kew JN, Levet-Trafit B, Lorez HP, Malherbe P, Miss MT, Mutel V, Pinard E, Roever S, Schmitt M, Trube G, Wybrecht R, Wyler R, Kemp JA.

J Pharmacol Exp Ther. 2002 Sep;302(3):940-8.

PMID:
12183650
42.

Severe impairment of NMDA receptor function in mice carrying targeted point mutations in the glycine binding site results in drug-resistant nonhabituating hyperactivity.

Ballard TM, Pauly-Evers M, Higgins GA, Ouagazzal AM, Mutel V, Borroni E, Kemp JA, Bluethmann H, Kew JN.

J Neurosci. 2002 Aug 1;22(15):6713-23.

43.

Donepezil reverses a mnemonic deficit produced by scopolamine but not by perforant path lesion or transient cerebral ischaemia.

Higgins GA, Enderlin M, Fimbel R, Haman M, Grottick AJ, Soriano M, Richards JG, Kemp JA, Gill R.

Eur J Neurosci. 2002 Jun;15(11):1827-40.

PMID:
12081663
44.

Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis.

Pepys MB, Herbert J, Hutchinson WL, Tennent GA, Lachmann HJ, Gallimore JR, Lovat LB, Bartfai T, Alanine A, Hertel C, Hoffmann T, Jakob-Roetne R, Norcross RD, Kemp JA, Yamamura K, Suzuki M, Taylor GW, Murray S, Thompson D, Purvis A, Kolstoe S, Wood SP, Hawkins PN.

Nature. 2002 May 16;417(6886):254-9.

PMID:
12015594
45.

Role of caspase-3 activation in cerebral ischemia-induced neurodegeneration in adult and neonatal brain.

Gill R, Soriano M, Blomgren K, Hagberg H, Wybrecht R, Miss MT, Hoefer S, Adam G, Niederhauser O, Kemp JA, Loetscher H.

J Cereb Blood Flow Metab. 2002 Apr;22(4):420-30.

PMID:
11919513
46.

A combined pharmacological and genetic approach to investigate the role of orphanin FQ in learning and memory.

Higgins GA, Kew JN, Richards JG, Takeshima H, Jenck F, Adam G, Wichmann J, Kemp JA, Grottick AJ.

Eur J Neurosci. 2002 Mar;15(5):911-22.

PMID:
11906533
47.

Clinical course and visual function in a family with mutations in the RPE65 gene.

Felius J, Thompson DA, Khan NW, Bingham EL, Jamison JA, Kemp JA, Sieving PA.

Arch Ophthalmol. 2002 Jan;120(1):55-61.

PMID:
11786058
48.

Analysis of photoreceptor function and inner retinal activity in juvenile X-linked retinoschisis.

Khan NW, Jamison JA, Kemp JA, Sieving PA.

Vision Res. 2001 Dec;41(28):3931-42.

49.

Identification of essential residues involved in the glutamate binding pocket of the group II metabotropic glutamate receptor.

Malherbe P, Knoflach F, Broger C, Ohresser S, Kratzeisen C, Adam G, Stadler H, Kemp JA, Mutel V.

Mol Pharmacol. 2001 Nov;60(5):944-54.

PMID:
11641422
50.

Positive allosteric modulators of metabotropic glutamate 1 receptor: characterization, mechanism of action, and binding site.

Knoflach F, Mutel V, Jolidon S, Kew JN, Malherbe P, Vieira E, Wichmann J, Kemp JA.

Proc Natl Acad Sci U S A. 2001 Nov 6;98(23):13402-7. Epub 2001 Oct 23. Erratum in: Proc Natl Acad Sci U S A 2001 Dec 18;98(26):15393.

Supplemental Content

Support Center